Search

Your search keyword '"Varaldo, R."' showing total 188 results
Start Over Author "Varaldo, R."
188 results on '"Varaldo, R."'

6. Second haploidentical stem cell transplantation for primary graft failure

Author

Giammarco, S., Raiola, A. M., Di Grazia, C., Bregante, S., Gualandi, F., Varaldo, R., Chiusolo, Patrizia, Sora', Federica, Sica, Simona, Laurenti, Luca, Metafuni, Elisabetta, Innocenti, Idanna, Autore, Francesco, Murgia, B., Bacigalupo, Andrea, Angelucci, E., Chiusolo P. (ORCID:0000-0002-1355-1587), Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), Laurenti L. (ORCID:0000-0002-8327-1396), Metafuni E., Innocenti I., Autore F., Bacigalupo A. (ORCID:0000-0002-9119-567X), Giammarco, S., Raiola, A. M., Di Grazia, C., Bregante, S., Gualandi, F., Varaldo, R., Chiusolo, Patrizia, Sora', Federica, Sica, Simona, Laurenti, Luca, Metafuni, Elisabetta, Innocenti, Idanna, Autore, Francesco, Murgia, B., Bacigalupo, Andrea, Angelucci, E., Chiusolo P. (ORCID:0000-0002-1355-1587), Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), Laurenti L. (ORCID:0000-0002-8327-1396), Metafuni E., Innocenti I., Autore F., and Bacigalupo A. (ORCID:0000-0002-9119-567X)

Abstract

We report the outcome of 19 patients who experienced primary graft failure (PrGF) after a haploidentical (HAPLO), unmanipulated bone marrow transplant. The median age of patients was 52 years; the conditioning regimen of the first HAPLO transplant was either full dose total body irradiation (TBI) or fludarabine, busulfan, and thiotepa (TBF); PTCY was given to all patients together with cyclosporine and mycophenolate. All 19 patients with PrGF received a second HAPLO graft, at a median interval of 42 days (34–82) after HSCT, using the Baltimore protocol and G-CSF mobilized PB from the same (n = 13) or another HAPLO family donor (n = 6). GvHD prophylaxis was again PTCY-based; 14/19 patients had trilineage recovery (74%) and 1-year survival was 66%. Engraftment at second HAPLO was seen in 7/8 patient with, and in 5/7 patients without donor-specific antibodies (DSA). In a multivariate logistic regression analysis on the original group of 503 patients, there was a trend for a reduced dose of busulfan, to increase the risk of PrGF (p = 0.1). In conclusion, patients with PrGF following a HAPLO transplant, can be rescued with a second early HAPLO transplant, using the same or a different donor.

Published
2021

18. Aggressive multiple sclerosis: a single‐centre, real‐world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab

Author

Boffa, G., primary, Lapucci, C., additional, Sbragia, E., additional, Varaldo, R., additional, Raiola, A. M., additional, Currò, D., additional, Roccatagliata, L., additional, Capello, E., additional, Laroni, A., additional, Mikulska, M., additional, Gualandi, F., additional, Uccelli, A., additional, Angelucci, E., additional, Mancardi, G. L., additional, and Inglese, M., additional

Published
2020
Full Text
View/download PDF

19. Intrabone marrow transplantation of cord blood cells is associated with better platelet recovery and decreased acute GvHD as compared with intravenous transplantation: an EUROCORD matched-paired analysis: O106

Author

Frassoni, F., Labopin, M., Gualandi, F., Sanchez-Guijo, F., Berger, M., Rovira, M., Podestà, M., Raiola, A. M., Ubezio, G., Varaldo, R., Caballero, D., Carreras, E., Nesi, F., Gobbi, M., Fagioli, F., Baciglaupo, A., Sacchi, N., Ionescu, I., Gluckman, E., and Rocha, V.

Published
2009

20. S1624 A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS

Author

Metafuni, E., primary, Cavattoni, I., additional, Lamparellli, T., additional, Raiola, A.M., additional, Ghiso, A., additional, Galaverna, F., additional, Gualandi, F., additional, Di Grazia, C., additional, Dominietto, A., additional, Varaldo, R., additional, Van Lint, M.T., additional, Angelucci, E., additional, and Bacigalupo, A., additional

Published
2019
Full Text
View/download PDF

23. Improved Outcome of alternative donor transplantation in patients with myelofibrosis: From unrelated to haploidentical family donors

Author

Bregante, S., Dominietto, A., Ghiso, A., Raiola, A. M., Gualandi, F., Varaldo, R., Di Grazia, C., Lamparelli, T., Luchetti, S., Geroldi, S., Casarino, L., Pozzi, S., Tedone, E., Van Lint, M. T., Galaverna, F., Barosi, G., Bacigalupo, Andrea, Bacigalupo A. (ORCID:0000-0002-9119-567X), Bregante, S., Dominietto, A., Ghiso, A., Raiola, A. M., Gualandi, F., Varaldo, R., Di Grazia, C., Lamparelli, T., Luchetti, S., Geroldi, S., Casarino, L., Pozzi, S., Tedone, E., Van Lint, M. T., Galaverna, F., Barosi, G., Bacigalupo, Andrea, and Bacigalupo A. (ORCID:0000-0002-9119-567X)

Abstract

This is a retrospective analysis of 95 patients with myelofibrosis who were allografted between 2001 and 2014. The aims of the study were to assess whether the outcome of alternative donor grafts has improved with time and how this compares with the outcome of identical sibling grafts. Patients were studied in 2 time intervals: 2000 to 2010 (n = 58) and 2011 to 2014 (n = 37). The Dynamic International Prognostic Scoring System score was comparable in the 2 time periods, but differences in the most recent group included older age (58 versus 53 years, P = .004), more family haploidentical donors (54% versus 5%, P < .0001), and the introduction of the thiotepa-fludarabine-busulfan conditioning regimen (70% of patients versus 2%, P < .0001). Acute and chronic graft-versus-host disease were comparable in the 2 time periods. The 3-year transplantation-related mortality (TRM) in the 2011 to 2014 period versus the 2000 to 2010 period is 16% versus 32% (P = .10), the relapse rate 16% versus 40% (P = .06), and actuarial survival 70% versus 39% (P = .08). Improved survival was most pronounced in alternative donor grafts (69% versus 21%, P = .02), compared with matched sibling grafts (72% versus 45%, P = .40). In conclusion, the outcome of allografts in patients with myelofibrosis has improved in recent years because of a reduction of both TRM and relapse. Improvement is most significant in alternative donor transplantations, with modifications in donor type and conditioning regimen.

Published
2016

28. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up (on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia)

Author

Palandri, F, Castagnetti, F, Testoni, N, Luatti, S, Marzocchi, G, Bassi, S, Breccia, M, Alimena, G, Pungolino, E, REGE CAMBRIN, G, Varaldo, R, Miglino, M, Specchia, G, Zuffa, E, Ferrara, F, Bocchia, Monica, Saglio, G, Pane, F, Alberti, D, Martinelli, G, Baccarani, M, and Rosti, G.

Published
2008

34. DLI after haploidentical BMT with post-transplant CY

Author

Ghiso, A, primary, Raiola, A M, additional, Gualandi, F, additional, Dominietto, A, additional, Varaldo, R, additional, Van Lint, M T, additional, Bregante, S, additional, Di Grazia, C, additional, Lamparelli, T, additional, Galaverna, F, additional, Stasia, A, additional, Luchetti, S, additional, Geroldi, S, additional, Grasso, R, additional, Colombo, N, additional, and Bacigalupo, A, additional

Published
2014
Full Text
View/download PDF

35. PEG-Intron in essential thrombocythaemia: two years treatment evaluation

Author

Gugliotta, L, Bulgarelli, S, Vianelli, N, Russo, D, Gamberi, B, Candoni, A, Michelutti, T, Imovilli, A, Rupoli, S, Barulli, S, Tassetti, A, Latagliata, R, Frattarelli, N, Sacchi, S, Montani, Ni, A, Mammi, C, Martinelli, V, Ciancia, R, Zanchini, A, Zumaglini, F, DE BIASI, E, Bucalos, Si, A, Gentili, S, Mazzotta, S, Tabilio, A, Marcomigni, L, Passamonti, F, Malabarba, L, Migli, No, M, Varaldo, R, Grossi, A, Balestri, F, Cacciola, Emma, Cacciola, Rossella Rosaria, Pisapia, G, Pogliani, E, Bonifazi, F, Fanin, R, Leoni, P, Mandelli, F, Rotoli, B, Zaccaria, A, Lauria, F, Martelli, M, Lazzarino, M, Gobbi, M, Bosi, A, Giustolisi, R, Mazza, P, Bovini, L, Pisarra, P, Fincato, G, and Baccarani, M.

Published
2003

38. PEG Intron in essential thrombocythemai: two years tretament in 90 patients

Author

Gugliotta, L., Bulgarelli, S., Vinelli, N., Russo, D., Candoni, A., Michelutti, T., Ruoli, S., Barulli, S., Latagliata, R., Sacchi, S., Martinelli, V., Ciancia, R., Zumaglini, F., DE BIASI, E., Bucalossi, A., Mazzotta, S., Tabilio, A., Marcomigni, L., Passamonti, F., Malabarba, L., Miglino, M, Varaldo, R., Balestri, F., Grossi, A., Cacciola, E., Cacciola, Rossella Rosaria, Pisapia, G., Boni, F., Fazi, Fanin, R., Leoni, P., Mandelli, F., Rotoli, B., Zaccaria, A., Lauria, F., Martinelli, M., Lazzarino, M, Gobbi, M., Bosi, A., Giustolisi, R., Mazza, P., Fincato, G., and Baccarani, M.

Published
2003

39. Implications for managerial and industrial policy

Author

Coltorti, F., Resciniti, R., Tunisini, A., Varaldo, R., Coltorti, Fulvio, Coltorti, F (ORCID:0000-0001-8701-5739), Coltorti, F., Resciniti, R., Tunisini, A., Varaldo, R., Coltorti, Fulvio, and Coltorti, F (ORCID:0000-0001-8701-5739)

Abstract

This volume aims at diffusing at international level the issue of midsized enterprises which are increasingly considered as a tool for the strengthening of the manufacturing industry. The volume contains either quantity or quality analyses based on statistics on the universe of Italian firms and examining 23 case studies. A contribution on German Mittelstand is also included, by operating a comparison with Italian manufacturing midsized firms.

Published
2013

40. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma

Author

Raiola, A, primary, Dominietto, A, additional, Varaldo, R, additional, Ghiso, A, additional, Galaverna, F, additional, Bramanti, S, additional, Todisco, E, additional, Sarina, B, additional, Giordano, L, additional, Ibatici, A, additional, Santoro, A, additional, Clavio, M, additional, Bacigalupo, A, additional, and Castagna, L, additional

Published
2013
Full Text
View/download PDF

41. Peg Interferon a- 2b (Peg Intron) in essential Thrombocythemia

Author

Gugliotta, L, Bulgarelli, S, Vinelli, N, Russo, D, Gamberi, B, Candoni, A, Ruoli, S, Barulli, S, Latagliata, R, Frattarelli, N, Sacchi, S, Serbano, S, Martinelli, V, Ciancia, R, Molinari, A. L, DE BIASI, E, Bucalossi, A, Tabilio, A, Marcomigni, L, Passamonti, F, Miglino, M, Varaldo, R, Grossi, A, Cacciola, Emma, Cacciola, Rossella Rosaria, Pisapia, G, Gentili, S, Pogliani, E, Fincato, G, Baccarani, M., L., Gugliotta, S., Bulgarelli, N., Vianelli, D., Russo, B., Gamberi, A., Candoni, S., Rupoli, S., Barulli, R., Latagliata, N., Frattarelli, S., Sacchi, S., Nerbano, Martinelli, Vincenzo, R., Ciancia, A. L., Molinari, E., DE BIASI, A., Bucalossi, A., Tabilio, L., Marcamigni, F., Passamonti, M., Miglino, R., Varaldo, A., Grossi, E., Cacciola, R., Cacciola, G., Pisapia, S., Gentili, E., Pogliani, G., Fincato, and M., Baccarani

Abstract

BLOOD, VOL 100 N.RO 11

Published
2002

46. I rapporti con il mercato delle medie imprese italiane: risultati di una case study research

Author

Jean-Claude Andreani, Umberto Collesei, Varaldo, R, Dalli, D, Resciniti, R, Tunisini, Annalisa, Tunisini, Annalisa (ORCID:0000-0003-2062-7479), Jean-Claude Andreani, Umberto Collesei, Varaldo, R, Dalli, D, Resciniti, R, Tunisini, Annalisa, and Tunisini, Annalisa (ORCID:0000-0003-2062-7479)

Abstract

Il paper analizza il ruolo del marketing nelle strategie competitive delle medie imprese industriali italiane di successo. In particolare, si individuano le loro scelte di posizionamento, e si esamina attraverso quali politiche di branding, pricing e comunicazione e quali relazioni di canale esse sono realizzate, The paper analyzes the role of marketing in the competitive strategies of the succesfful midsize manufacturing companies. The paper focalizes to positioning strategies and to more relevant marketing mix policies.

Published
2009

50. Franchising e internazionalizzazione delle imprese

Author

Varaldo, R., ALESSANDRO GANDOLFO, and Amoroso, Marisa

Subjects
Franchising, Distribution, Franchising, Internazionalizzazione
Abstract

Lo studio dei processi di internazionalizzazione attraverso il franchising rappresenta un tema relativamente recente e soltanto a partire dagli ultimi anni il fenomeno ha assunto una rilevanza apprezzabile. Le reti in franchising internazionalizzate, vale a dire i sisetmi in franchising che si sono insediati all'esterno del proprio paese di origine rappresentano una quaota significativamente inferiore rispetto al totale delle reti in attività.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results